Filtered By:
Vaccination: Hepatitis Vaccine
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 256 results found since Jan 2013.
Hepatitis C
is a recently discovered disease. Harvey J. Alter identified the variant form of Hepatitis during the 70s, which then became known as a ‘non-A, non-B Hepatitis (NANBH)’. In the 1980s, Michael Houghton and his team isolated the genome of the new virus, and it was named ‘Hepatitis C’. Finally, in 1997 Charles M. Rice proved that the virus is a disease agent, capable of acting alone to cause Hepatitis.
This year’s Nobel Prize in Medicine has been jointly awarded to Harvey J. Alter, Michael Houghton, and Charles M. Rice for the discovery of the virus. Their contributions (illustrated below) have led to improved unde...
Source: GIDEON blog - November 10, 2020 Category: Databases & Libraries Authors: Kristina Symes Tags: Epidemiology News Source Type: blogs
SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Global Head, Janss...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news
U.S. FDA Approves New Pediatric Formulation of SIRTURO ® (bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis
NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO®
(bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided. This indication received accelerated appro...
Source: Johnson and Johnson - May 27, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion available...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Hepatitis A
virus (HAV) is a positive-strand RNA virus that is transmitted feco-orally through person-to-person contact. Outbreaks are often linked to poor sanitation, overcrowding, or food and water contamination. Infection is often asymptomatic in children, but adults present with jaundice, abdominal pain, hepatitis, and hyperbilirubinemia. Diagnosis is through detection of immunoglobulin M antibodies against HAV, and treatment is supportive. Vaccination is the mainstay of prevention and should be given before exposure whenever possible.
Source: Gastroenterology Clinics of North America - March 28, 2020 Category: Gastroenterology Authors: Ameer Abutaleb, Shyam Kottilil Source Type: research
Janssen Announces Health Canada Approval of CABENUVA ™, the First Long-Acting Regimen for the Treatment of HIV
Cork, Ireland, March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Health Canada has approved CABENUVA™ (cabotegravir and rilpivirine extended release injectable suspensions), the first and only once-monthly, long-acting regimen for the treatment of HIV-1 infection in adults. CABENUVA™ is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]). CABENUVA™, a co-packaged kit with two separate inj...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Effectiveness and comparison of various Non-Pharmacological methods of analgesia in newborns.
Conclusion: Oral sucrose and non-nutritive sucking are simple yet underutilized non-pharmacological interventions which effectively reduce the pain in newborns.
PMID: 31431605 [PubMed - as supplied by publisher]
Source: Korean Journal of Pediatrics - August 23, 2019 Category: Pediatrics Tags: Korean J Pediatr Source Type: research
What Infectious Diseases are Important to Consider in Transplantation Patients?
Discussion
Transplantation is not a common problem for primary care physicians but when a child’s disease has progressed to end-stage organ failure, transplantation can be the only treatment available. While the primary care provider usually is not involved in the daily management of patients before, during and after transplantation, they can be involved in many areas. These can include providing appropriate primary and acute care, ordering and obtaining necessary medical tests, medications and equipment, assisting with medical insurance, providing medical history and records to consultants, translating medical infor...
Source: PediatricEducation.org - June 24, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Pneumococcal conjugate vaccines for preventing acute otitis media in children.
CONCLUSIONS: Administration of the licenced CRM197-PCV7 and PHiD-CV10 during early infancy is associated with large relative risk reductions in pneumococcal AOM. However, the effects of these vaccines on all-cause AOM is far more uncertain. We found no evidence of a beneficial effect on all-cause AOM of administering PCVs in high-risk infants, after early infancy (i.e. in children one year and above), and in older children with a history of respiratory illness. Compared to control vaccines, PCVs were associated with an increase in mild local reactions (redness, swelling), fever, and pain and/or tenderness. We found no evid...
Source: Cochrane Database of Systematic Reviews - May 27, 2019 Category: General Medicine Authors: Fortanier AC, Venekamp RP, Boonacker CW, Hak E, Schilder AG, Sanders EA, Damoiseaux RA Tags: Cochrane Database Syst Rev Source Type: research
Potent Inhibition of Zika Virus Replication by Aurintricarboxylic Acid
In this study, we evaluated ATA as a potential antiviral drug against ZIKV replication. The antiviral activity of ATA against ZIKV replication in vitro showed median inhibitory concentrations (IC50) of 13.87 ± 1.09 μM and 33.33 ± 1.13 μM in Vero and A549 cells, respectively; without showing any cytotoxic effect in both cell lines (median cytotoxic concentration (CC50)> 1,000 μM). Moreover, ATA protected both cell types from ZIKV-induced cytopathic effect (CPE) and apoptosis in a time- and concentration-dependent manner. In addition, pre-treatment of Vero cells with ATA for up to 72 h also...
Source: Frontiers in Microbiology - April 11, 2019 Category: Microbiology Source Type: research
Next-Generation Cancer Immunotherapy Targeting Glypican-3
This study was supported in part by the National Cancer Center Research and Development Fund (25-A-7 and 28-A-8); Health and Labor Science Research Grants for Clinical Research, Japan; and joint research funding from Takeda Pharmaceutical Co, Ltd.; Noile-Immune Biotech Inc.; Ono Pharmaceutical Co., Ltd.; BrightPath Biotherapeutics Co., Ltd.; and Sysmex Co., Ltd. This study was performed as part of a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan.
Conflict of Interest Statement
TN, TS, and TY ...
Source: Frontiers in Oncology - April 9, 2019 Category: Cancer & Oncology Source Type: research
Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial
Conclusions: These finding suggest that Poly-ICLC could be safely used for inducing transient innate immune responses in treated HIV+ subjects indicating promise as an adjuvant for HIV therapeutic vaccines.
Trial Registration: www.ClinicalTrials.gov, identifier: NCT02071095.
Introduction
Innate immune dysregulation during HIV infection hinders the formation of anti-HIV adaptive immunity (1–6) resulting in rampant viral dissemination and progression to AIDS. Adherence to combination anti-retroviral therapy (cART) regimens controls viremia, restores CD4+T cell counts and reverses immune dysfunction to ...
Source: Frontiers in Immunology - April 8, 2019 Category: Allergy & Immunology Source Type: research
2019 Health Law Professors Conference
Conclusion
Source: blog.bioethics.net - March 27, 2019 Category: Medical Ethics Authors: Thaddeus Mason Pope, JD, PhD Tags: Health Care syndicated Source Type: blogs
What Is This International Traveler's Diagnosis?
BY GREGORY TAYLOR, DO; DAWN ZELENKA-JOSHOWITZ, DO; & ANDREW TAECKER, DOA 34-year-old man presented with intermittent fever and body aches for 10 days. He had been visiting family in India, and the symptoms began when he returned home. His fever had been as high as 104°F, and he was experiencing nausea, two episodes of bilious emesis, body aches, nonspecific abdominal pain, and multiple episodes of watery, nonbloody diarrhea.He said he knew of no tuberculosis exposure or ill contacts, and he was current on his routine influenza and hepatitis A vaccines. His temperature was 101.4°F (he had taken acetaminophen three ...
Source: The Case Files - December 12, 2018 Category: Emergency Medicine Tags: Blog Posts Source Type: research
